Fangfei Nie

Fangfei Nie

Auto-generated profile, based on publicly available information

Fangfei Nie

Department of Plastic Surgery, Peking University Third Hospital, Beijing, P.R. China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Photomedicine and Laser Surgery
Verified
Journal Article
Closed access
JMJian-Xun Ma
Jian-Xun Ma
QYQingmo Yang
Qingmo Yang
YXYou-Chen Xia
You-Chen Xia
WZWeiguang Zhang
Weiguang Zhang
FNFang-Fei Nie
Fang-Fei Nie
Objective: To investigate the effect of 810 nm near-infrared (NIR) laser on the revascularization of ischemic flaps. Background: It has long been proved that photobiomodulation therapy (PBMT) improves the blood supply of flaps. NIR laser improves the treatment of hypodermis-located lesions and of flap survival, but basic research on the use of 810 nm NIR laser for ischemic flap revascularization is still lacking. Materials and methods: We prepared two symmetrical long random-pattern flaps on the backs of 60 rats. Each flap was 6 cm long, 1 cm wide, and 1 cm to the middle line. The flaps were divided into an irradiated flap group and an internal control group. The irradiated flaps underwent postoperative 810 nm laser therapy with the energy density of 11.30 J/cm 2 daily. The control flaps were covered by stainless steel to avoid laser irradiation. We observed the viability of the flaps. The flaps underwent Hematoxylin and Eosin (H&E) staining for the observation of histomorphology, immunohistochemical staining of factor VIII for the capillary count, α-smooth muscle actin for the small arterial count, and vascular endothelial growth factor for the integrated optical density (OD) of the positive stained color. Results: The irradiated flaps showed significantly better flap survival than the control flaps. H&E staining showed that the irradiated flaps had clear tissue structure and little inflammatory cell infiltration. The control flaps demonstrated comparatively worse results. Vascular endothelial growth factor staining showed that the difference in integrated OD between the irradiated flaps and the control flaps was not statistically significant. α-smooth muscle actin and factor VIII staining showed significantly greater numbers of arterioles and capillaries in the irradiated flaps than the control flaps after 4 days of irradiation. Conclusions: PBMT with 810 nm NIR laser could enhance ischemic flap revascularization and increase flap viability.

13 February 2024 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
MZMinhui Zhu
Minhui Zhu
YMYi Ma
Yi Ma
WWWei Wang
Wei Wang
MLMeng Li
Meng Li
SCShicai Chen
Shicai Chen
CZCaiyun Zhang
Caiyun Zhang
Tongue squamous cell carcinoma (TSCC) is the main pathologic subtype of oral cancer, and the current therapeutic effect is far from satisfactory. The signal peptide-CUB-EGF domain-containing protein 3 (SCUBE3) has been shown to be a tumor-promoting factor in several malignancies. However, little is known about the role of SCUBE3 in TSCC. In this study, we identified that SCUBE3 was highly expressed in TSCC. Clinically, high expression of SCUBE3 was positively associated with tumor stage and T stage of TSCC. Functionally, SCUBE3 silence remarkably restrained cell proliferation, migration, and invasion, induced apoptosis as well as cell cycle arrest in G2-phase, and weakened the tumorigenicity of TSCC cells in vivo. Mechanistically, SCUBE3 promoted the direct binding of CCAAT enhancer binding protein alpha (CEBPA) to C-C motif chemokine ligand 2 (CCL2) promoter in TSCC cells. Interestingly, CCL2 overexpression partially reversed the inhibitory effect of SCUBE3 deficiency on TSCC cell viability and migration. Moreover, STAT3 signaling contributed to CCL2-mediated phenotypes in TSCC cells. Implications: Our data revealed a tumor-promoting role for SCUBE3 in TSCC via the CEBPA/CCL2/STAT3 axis, which provided new insight into novel potential therapeutic target for TSCC.

2 May 2024
Verified
Other
Open access
MZMinhui Zhu
Minhui Zhu
YMYi Ma
Yi Ma
WWWei Wang
Wei Wang
MLMeng Li
Meng Li
SCShicai Chen
Shicai Chen
CZCaiyun Zhang
Caiyun Zhang
Table S3. Antibodies applied in Western blot and co-IP assay of this research.


2 May 2024
Verified
Other
Open access
MZMinhui Zhu
Minhui Zhu
YMYi Ma
Yi Ma
WWWei Wang
Wei Wang
MLMeng Li
Meng Li
SCShicai Chen
Shicai Chen
CZCaiyun Zhang
Caiyun Zhang
Supplementary Figure 1. Validation of three SCUBE3 shRNA clones was performed by qPCR analysis. Results were presented as mean ± SD. **P<0.01.

2 May 2024
Verified
Other
Open access
MZMinhui Zhu
Minhui Zhu
YMYi Ma
Yi Ma
WWWei Wang
Wei Wang
MLMeng Li
Meng Li
SCShicai Chen
Shicai Chen
CZCaiyun Zhang
Caiyun Zhang
Supplementary Figure 1. Validation of three SCUBE3 shRNA clones was performed by qPCR analysis. Results were presented as mean ± SD. **P<0.01.